Pay in 4 interest-free payments of $5.89 Learn more
Ships within 48 hours · Estimated delivery Aug 15 - Aug 20
The actual evaluation of cardiovascular benefits will be achieved with the completion of the Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results (LEADER) trial, which enrolled 9,340 T2D patients randomized for treatment with liraglutide or placebo for an estimated period of 5 years (ClinicalTrials.gov Identifier: NCT01179048)
Do not take this product if taking the following medications: 5-fluorouracil, ACE inhibitors, activated charcoal, aminoglycoside antibiotics, amiodarone, antacids, anticoagulants/antiplatelet drugs, antidiabetic drugs, antihypertensive drugs, atazanavir, bisphosphonates, blood thinners, calcium channel blockers, capecitabine, cephalexin, chloroquine, cisplatin, digoxin, fosphenytoin, integrase inhibitors, levodopa/carbidopa, methotrexate, nitroglycerin, phenobarbital, penicillamine, phenytoin, potassium-sparing diuretics, primidone, pyrimethamine, quinolone antibiotics, ritonavir, skeletal muscle relaxants, sulfonylureas, and/or tetracycline antibiotics
When bound to copper, the peptide silences coppers redox activity, preventing toxic free copper effects while enabling safe copper delivery into cells
Acylated and non-acylated tirzepatide displayed reduced potencies in eliciting GIPR- or GLP-1R-mediated cAMP responses (Fig
US$ 27.48
US$ 24.03
US$ 26.73
